Toward Noninvasive High‐Resolution In Vivo pH Mapping in Brain Tumors by <sup>31</sup>P‐Informed deepCEST MRI

Jan‐Rüdiger Schüre(Friedrich-Alexander-Universität Erlangen-Nürnberg), Moritz Zaiß(Friedrich-Alexander-Universität Erlangen-Nürnberg), Andreas Maier(Friedrich-Alexander-Universität Erlangen-Nürnberg), Ralf Deichmann(Goethe University Frankfurt), Eike Steidl(Goethe University Frankfurt), Manoj Shrestha(Max Planck Institute for Human Cognitive and Brain Sciences), Armin M. Nagel(Friedrich-Alexander-Universität Erlangen-Nürnberg), Elke Hattingen(Goethe University Frankfurt), Arnd Dörfler(University Medical Center Groningen), Junaid R. Rajput(Friedrich-Alexander-Universität Erlangen-Nürnberg)
NMR in Biomedicine
May 15, 2025
10.1002/nbm.70060
Cited by 3

Related Papers

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
|The Lancet|2019|581
Pros and cons of ultra-high-field MRI/MRS for human application
|Progress in Nuclear Magnetic Resonance Spectroscopy|2018|542
Mutations in the Pericentrin ( <i>PCNT</i> ) Gene Cause Primordial Dwarfism
|Science|2008|397
Perfusion MRI: The Five Most Frequently Asked Technical Questions
|American Journal of Roentgenology|2012|357
Perfusion MRI: The Five Most Frequently Asked Clinical Questions
|American Journal of Roentgenology|2013|347